Xtant Medical (XTNT) investor relations material

Market opportunity and business focus

• Targets a $3 billion US orthobiologics market with over $10 billion in adjacent opportunities.

• Focuses on high-margin orthobiologics and diversification into adjacent markets like nerve regeneration and wound care.

• Vertically integrated manufacturing enhances margins and supply chain control.

• Broad commercial reach with ~450 hospital system contracts and 500+ independent distributors.

• Recent sale of non-core assets sharpened focus and reduced long-term debt by nearly 50%.

Product portfolio and innovation

• Offers a full suite of biologics and fixation products, including viable bone matrix, growth factors, and synthetic bone grafts.

• Only orthobiologics company manufacturing all five major product categories.

• Recent innovations include next-generation DBM products, amniotic membrane allografts, and advanced synthetic grafts.

• Pipeline includes upgraded orthobiologics and expansion into extremities and advanced wound closure.

Financial performance and profitability

• FY 2025 revenue reached $133.9M, up 14% year-over-year, with positive net income, adjusted EBITDA, and operating cash flow.

• Gross margin improved to as high as 69% in 2025, with consistent positive adjusted EBITDA.

• Sale of non-core assets in Q4 2025 increased cash to over $22 million and reduced debt to $11.1 million.

• Operating leverage recognized as business scales, with strategic growth in OEM and contract manufacturing.